Drug Discovery Featured Articles & Applications

  1. Is Oncology Precision Medicine Coming of Age? 12/3/2025

    Developers are releasing new data suggesting that their targeted therapy candidates may finally address some of oncology’s toughest challenges.

  2. CROs In Early Drug Discovery, Part 2: Keeping Pace And Protecting Quality 12/3/2025

    Part 2 of this series covers how to maintain momentum and protect data quality.

  3. The Blue Crayfish: Turning Nature's Efficiency Into Safe, Bioavailable Therapeutics 12/1/2025

    Crayfish achieve incredibly rapid biomineralization — a physiological marvel that is now setting the stage for a new class of highly bioavailable mineral-based therapeutic agents.

  4. CROs In Early Drug Discovery, Part 1: Choosing The Right Partner 11/26/2025

    Part 1 of this series covers how to choose the right CRO partner and establish clear scientific expectations along with a well-defined statement of work.

  5. Antibody–Drug Conjugates 3.0: A New Era Of Precision Engineering In Oncology 11/25/2025

    The evolution of ADCs illustrates how advances in antibody engineering, linker chemistry, and conjugation technology can incrementally refine a therapeutic modality.

  6. GO‑4 Drug Combo Offers New Hope for Treating Late-Stage BRCA/PALB2-Mutated Cancers 11/24/2025

    General Oncology’s GO‑4 is an investigational product combining melphalan, BCNU, hydroxocobalamin, and ascorbic acid. The company's CEO, Jeff Glazier shared how the combo is designed to shut down DNA repair and resensitize hard‑to‑treat tumors to chemotherapy for patients with advanced pancreatic or breast cancer.

  7. Challenges And Opportunities For Reducing In Vivo Safety Assessment Testing With New Approach Methodologies 11/24/2025

    Although NAMs — such as organoids, organs-on-chips, MPS, and in silico models — have transformed preclinical science, they still face scientific, technical, and regulatory constraints.

  8. Rethinking The "3:1 Rule" In LNP Production 11/21/2025

    A new two-step, ideal-mixing strategy from MIT researchers shows how operating briefly in unstable regions of LNP assembly can unlock precise control of particle size and shape—advancing next-gen RNA manufacturing.

  9. From Funding Gaps to AI Frontiers: Insights from the Boston Globe Summit 2025 11/20/2025

    Insights from the Boston Globe Summit 2025 exploring biotech funding challenges, AI-driven drug discovery, and genome editing breakthroughs shaping the future of research and care.

  10. An End-To-End Automated HTP Platform For Cell Line Optimization 11/20/2025

    Bristol Myers Squibb's high-throughput stable CHO platform produces high-titer, high-quality material in a fraction of the conventional timeline.